Increasing the Antimicrobial Activity of Nisin-Based Lantibiotics against Gram-Negative Pathogens
Lantibiotics are ribosomally synthesized and posttranslationally modified antimicrobial compounds containing lanthionine and methyl-lanthionine residues. Nisin, one of the most extensively studied and used lantibiotics, has been shown to display very potent activity against Gram-positive bacteria, a...
Saved in:
Published in | Applied and environmental microbiology Vol. 84; no. 12; p. e00052-18 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Microbiology
15.06.2018
|
Subjects | |
Online Access | Get full text |
ISSN | 0099-2240 1098-5336 1098-5336 |
DOI | 10.1128/AEM.00052-18 |
Cover
Loading…
Abstract | Lantibiotics are ribosomally synthesized and posttranslationally modified antimicrobial compounds containing lanthionine and methyl-lanthionine residues. Nisin, one of the most extensively studied and used lantibiotics, has been shown to display very potent activity against Gram-positive bacteria, and stable resistance is rarely observed. By binding to lipid II and forming pores in the membrane, nisin can cause the efflux of cellular constituents and inhibit cell wall biosynthesis. However, the activity of nisin against Gram-negative bacteria is much lower than that against Gram-positive bacteria, mainly because lipid II is located at the inner membrane, and the rather impermeable outer membrane in Gram-negative bacteria prevents nisin from reaching lipid II. Thus, if the outer membrane-traversing efficiency of nisin could be increased, the activity against Gram-negative bacteria could, in principle, be enhanced. In this work, several relatively short peptides with activity against Gram-negative bacteria were selected from literature data to be fused as tails to the C terminus of either full or truncated nisin species. Among these, we found that one of three tails (tail 2 [T2; DKYLPRPRPV], T6 [NGVQPKY], and T8 [KIAKVALKAL]) attached to a part of nisin displayed improved activity against Gram-negative microorganisms. Next, we rationally designed and reengineered the most promising fusion peptides. Several mutants whose activity significantly outperformed that of nisin against Gram-negative pathogens were obtained. The activity of the tail 16 mutant 2 (T16m2) construct against several important Gram-negative pathogens (i.e.,
Escherichia coli
,
Klebsiella pneumoniae
,
Acinetobacter baumannii
,
Pseudomonas aeruginosa
,
Enterobacter aerogenes
) was increased 4- to 12-fold compared to that of nisin. This study indicates that the rational design of nisin can selectively and significantly improve its outer membrane-permeating capacity as well as its activity against Gram-negative pathogens.
IMPORTANCE
Lantibiotics are antimicrobial peptides that are highly active against Gram-positive bacteria but that have relatively poor activity against most Gram-negative bacteria. Here, we modified the model lantibiotic nisin by fusing parts of it to antimicrobial peptides with known activity against Gram-negative bacteria. The appropriate selection of peptidic moieties that could be attached to (parts of) nisin could lead to a significant increase in its inhibitory activity against Gram-negative bacteria. Using this strategy, hybrids that outperformed nisin by displaying 4- to 12-fold higher levels of activity against relevant Gram-negative bacterial species were produced. This study shows the power of modified peptide engineering to alter target specificity in a desired direction. |
---|---|
AbstractList | Lantibiotics are ribosomally synthesized and posttranslationally modified antimicrobial compounds containing lanthionine and methyl-lanthionine residues. Nisin, one of the most extensively studied and used lantibiotics, has been shown to display very potent activity against Gram-positive bacteria, and stable resistance is rarely observed. By binding to lipid II and forming pores in the membrane, nisin can cause the efflux of cellular constituents and inhibit cell wall biosynthesis. However, the activity of nisin against Gram-negative bacteria is much lower than that against Gram-positive bacteria, mainly because lipid II is located at the inner membrane, and the rather impermeable outer membrane in Gram-negative bacteria prevents nisin from reaching lipid II. Thus, if the outer membrane-traversing efficiency of nisin could be increased, the activity against Gram-negative bacteria could, in principle, be enhanced. In this work, several relatively short peptides with activity against Gram-negative bacteria were selected from literature data to be fused as tails to the C terminus of either full or truncated nisin species. Among these, we found that one of three tails (tail 2 [T2; DKYLPRPRPV], T6 [NGVQPKY], and T8 [KIAKVALKAL]) attached to a part of nisin displayed improved activity against Gram-negative microorganisms. Next, we rationally designed and reengineered the most promising fusion peptides. Several mutants whose activity significantly outperformed that of nisin against Gram-negative pathogens were obtained. The activity of the tail 16 mutant 2 (T16m2) construct against several important Gram-negative pathogens (i.e.,
Escherichia coli
,
Klebsiella pneumoniae
,
Acinetobacter baumannii
,
Pseudomonas aeruginosa
,
Enterobacter aerogenes
) was increased 4- to 12-fold compared to that of nisin. This study indicates that the rational design of nisin can selectively and significantly improve its outer membrane-permeating capacity as well as its activity against Gram-negative pathogens.
IMPORTANCE
Lantibiotics are antimicrobial peptides that are highly active against Gram-positive bacteria but that have relatively poor activity against most Gram-negative bacteria. Here, we modified the model lantibiotic nisin by fusing parts of it to antimicrobial peptides with known activity against Gram-negative bacteria. The appropriate selection of peptidic moieties that could be attached to (parts of) nisin could lead to a significant increase in its inhibitory activity against Gram-negative bacteria. Using this strategy, hybrids that outperformed nisin by displaying 4- to 12-fold higher levels of activity against relevant Gram-negative bacterial species were produced. This study shows the power of modified peptide engineering to alter target specificity in a desired direction. Lantibiotics are ribosomally synthesized and posttranslationally modified antimicrobial compounds containing lanthionine and methyl-lanthionine residues. Nisin, one of the most extensively studied and used lantibiotics, has been shown to display very potent activity against Gram-positive bacteria, and stable resistance is rarely observed. By binding to lipid II and forming pores in the membrane, nisin can cause the efflux of cellular constituents and inhibit cell wall biosynthesis. However, the activity of nisin against Gram-negative bacteria is much lower than that against Gram-positive bacteria, mainly because lipid II is located at the inner membrane, and the rather impermeable outer membrane in Gram-negative bacteria prevents nisin from reaching lipid II. Thus, if the outer membrane-traversing efficiency of nisin could be increased, the activity against Gram-negative bacteria could, in principle, be enhanced. In this work, several relatively short peptides with activity against Gram-negative bacteria were selected from literature data to be fused as tails to the C terminus of either full or truncated nisin species. Among these, we found that one of three tails (tail 2 [T2; DKYLPRPRPV], T6 [NGVQPKY], and T8 [KIAKVALKAL]) attached to a part of nisin displayed improved activity against Gram-negative microorganisms. Next, we rationally designed and reengineered the most promising fusion peptides. Several mutants whose activity significantly outperformed that of nisin against Gram-negative pathogens were obtained. The activity of the tail 16 mutant 2 (T16m2) construct against several important Gram-negative pathogens (i.e., Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter aerogenes) was increased 4- to 12-fold compared to that of nisin. This study indicates that the rational design of nisin can selectively and significantly improve its outer membrane-permeating capacity as well as its activity against Gram-negative pathogens.IMPORTANCE Lantibiotics are antimicrobial peptides that are highly active against Gram-positive bacteria but that have relatively poor activity against most Gram-negative bacteria. Here, we modified the model lantibiotic nisin by fusing parts of it to antimicrobial peptides with known activity against Gram-negative bacteria. The appropriate selection of peptidic moieties that could be attached to (parts of) nisin could lead to a significant increase in its inhibitory activity against Gram-negative bacteria. Using this strategy, hybrids that outperformed nisin by displaying 4- to 12-fold higher levels of activity against relevant Gram-negative bacterial species were produced. This study shows the power of modified peptide engineering to alter target specificity in a desired direction.Lantibiotics are ribosomally synthesized and posttranslationally modified antimicrobial compounds containing lanthionine and methyl-lanthionine residues. Nisin, one of the most extensively studied and used lantibiotics, has been shown to display very potent activity against Gram-positive bacteria, and stable resistance is rarely observed. By binding to lipid II and forming pores in the membrane, nisin can cause the efflux of cellular constituents and inhibit cell wall biosynthesis. However, the activity of nisin against Gram-negative bacteria is much lower than that against Gram-positive bacteria, mainly because lipid II is located at the inner membrane, and the rather impermeable outer membrane in Gram-negative bacteria prevents nisin from reaching lipid II. Thus, if the outer membrane-traversing efficiency of nisin could be increased, the activity against Gram-negative bacteria could, in principle, be enhanced. In this work, several relatively short peptides with activity against Gram-negative bacteria were selected from literature data to be fused as tails to the C terminus of either full or truncated nisin species. Among these, we found that one of three tails (tail 2 [T2; DKYLPRPRPV], T6 [NGVQPKY], and T8 [KIAKVALKAL]) attached to a part of nisin displayed improved activity against Gram-negative microorganisms. Next, we rationally designed and reengineered the most promising fusion peptides. Several mutants whose activity significantly outperformed that of nisin against Gram-negative pathogens were obtained. The activity of the tail 16 mutant 2 (T16m2) construct against several important Gram-negative pathogens (i.e., Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter aerogenes) was increased 4- to 12-fold compared to that of nisin. This study indicates that the rational design of nisin can selectively and significantly improve its outer membrane-permeating capacity as well as its activity against Gram-negative pathogens.IMPORTANCE Lantibiotics are antimicrobial peptides that are highly active against Gram-positive bacteria but that have relatively poor activity against most Gram-negative bacteria. Here, we modified the model lantibiotic nisin by fusing parts of it to antimicrobial peptides with known activity against Gram-negative bacteria. The appropriate selection of peptidic moieties that could be attached to (parts of) nisin could lead to a significant increase in its inhibitory activity against Gram-negative bacteria. Using this strategy, hybrids that outperformed nisin by displaying 4- to 12-fold higher levels of activity against relevant Gram-negative bacterial species were produced. This study shows the power of modified peptide engineering to alter target specificity in a desired direction. Lantibiotics are ribosomally synthesized and posttranslationally modified antimicrobial compounds containing lanthionine and methyl-lanthionine residues. Nisin, one of the most extensively studied and used lantibiotics, has been shown to display very potent activity against Gram-positive bacteria, and stable resistance is rarely observed. By binding to lipid II and forming pores in the membrane, nisin can cause the efflux of cellular constituents and inhibit cell wall biosynthesis. However, the activity of nisin against Gram-negative bacteria is much lower than that against Gram-positive bacteria, mainly because lipid II is located at the inner membrane, and the rather impermeable outer membrane in Gram-negative bacteria prevents nisin from reaching lipid II. Thus, if the outer membrane-traversing efficiency of nisin could be increased, the activity against Gram-negative bacteria could, in principle, be enhanced. In this work, several relatively short peptides with activity against Gram-negative bacteria were selected from literature data to be fused as tails to the C terminus of either full or truncated nisin species. Among these, we found that one of three tails (tail 2 [T2; DKYLPRPRPV], T6 [NGVQPKY], and T8 [KIAKVALKAL]) attached to a part of nisin displayed improved activity against Gram-negative microorganisms. Next, we rationally designed and reengineered the most promising fusion peptides. Several mutants whose activity significantly outperformed that of nisin against Gram-negative pathogens were obtained. The activity of the tail 16 mutant 2 (T16m2) construct against several important Gram-negative pathogens (i.e., Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter aerogenes) was increased 4- to 12-fold compared to that of nisin. This study indicates that the rational design of nisin can selectively and significantly improve its outer membrane-permeating capacity as well as its activity against Gram-negative pathogens. Lantibiotics are ribosomally synthesized and posttranslationally modified antimicrobial compounds containing lanthionine and methyl-lanthionine residues. Nisin, one of the most extensively studied and used lantibiotics, has been shown to display very potent activity against Gram-positive bacteria, and stable resistance is rarely observed. By binding to lipid II and forming pores in the membrane, nisin can cause the efflux of cellular constituents and inhibit cell wall biosynthesis. However, the activity of nisin against Gram-negative bacteria is much lower than that against Gram-positive bacteria, mainly because lipid II is located at the inner membrane, and the rather impermeable outer membrane in Gram-negative bacteria prevents nisin from reaching lipid II. Thus, if the outer membrane-traversing efficiency of nisin could be increased, the activity against Gram-negative bacteria could, in principle, be enhanced. In this work, several relatively short peptides with activity against Gram-negative bacteria were selected from literature data to be fused as tails to the C terminus of either full or truncated nisin species. Among these, we found that one of three tails (tail 2 [T2; DKYLPRPRPV], T6 [NGVQPKY], and T8 [KIAKVALKAL]) attached to a part of nisin displayed improved activity against Gram-negative microorganisms. Next, we rationally designed and reengineered the most promising fusion peptides. Several mutants whose activity significantly outperformed that of nisin against Gram-negative pathogens were obtained. The activity of the tail 16 mutant 2 (T16m2) construct against several important Gram-negative pathogens (i.e., , , , , ) was increased 4- to 12-fold compared to that of nisin. This study indicates that the rational design of nisin can selectively and significantly improve its outer membrane-permeating capacity as well as its activity against Gram-negative pathogens. Lantibiotics are antimicrobial peptides that are highly active against Gram-positive bacteria but that have relatively poor activity against most Gram-negative bacteria. Here, we modified the model lantibiotic nisin by fusing parts of it to antimicrobial peptides with known activity against Gram-negative bacteria. The appropriate selection of peptidic moieties that could be attached to (parts of) nisin could lead to a significant increase in its inhibitory activity against Gram-negative bacteria. Using this strategy, hybrids that outperformed nisin by displaying 4- to 12-fold higher levels of activity against relevant Gram-negative bacterial species were produced. This study shows the power of modified peptide engineering to alter target specificity in a desired direction. |
Author | Li, Qian Kuipers, Oscar P. Montalban-Lopez, Manuel |
Author_xml | – sequence: 1 givenname: Qian surname: Li fullname: Li, Qian organization: Department of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, the Netherlands – sequence: 2 givenname: Manuel surname: Montalban-Lopez fullname: Montalban-Lopez, Manuel organization: Department of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, the Netherlands, Department of Microbiology, Faculty of Sciences, University of Granada, Granada, Spain – sequence: 3 givenname: Oscar P. surname: Kuipers fullname: Kuipers, Oscar P. organization: Department of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, the Netherlands |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29625984$$D View this record in MEDLINE/PubMed |
BookMark | eNptkb1vFDEQxS0URC6BjhpZoqFgw9jeD7tBukQhRDoCBdTWrNe752jXDrYvUv57fCRBEFFNMb95evPeETnwwVtCXjM4YYzLD-vzLycA0PCKyWdkxUDJqhGiPSArAKUqzms4JEcpXReqhla-IIdctbxRsl4RvPQmWkzOTzRvLV377BZnYugdznRtsrt1-Y6GkV65AlWnmOxAN1iw3oXsTKI4ofMp04uIS3VlJyw3ln7DvA2T9ekleT7inOyrh3lMfnw6_372udp8vbg8W28qI2qeq152zSgGBDYClwijANZ1fWulFMbwrqkbGOQg1ahwFGiFRS5YK6USA1iU4ph8vNe92fWLHYz1OeKsb6JbMN7pgE7_u_Fuq6dwq0sQDDooAu8eBGL4ubMp68UlY-cZvQ27pDlwriQXqivo2yfoddhFX94rVCdqpUrohXrzt6M_Vh7TLwC_B0reKUU7auNyiS_sDbpZM9D7inWpWP-uWLP9n--fHD3q_hf_Ba6_p1c |
CitedBy_id | crossref_primary_10_1021_acs_chemrev_2c00210 crossref_primary_10_1093_femsle_fnae031 crossref_primary_10_26508_lsa_202302509 crossref_primary_10_3390_pr12081766 crossref_primary_10_1016_j_ijfoodmicro_2020_109007 crossref_primary_10_1080_17460441_2020_1699530 crossref_primary_10_1080_17460441_2024_2441351 crossref_primary_10_1016_j_jhazmat_2024_133976 crossref_primary_10_1016_j_jddst_2023_105246 crossref_primary_10_3390_foods13111606 crossref_primary_10_1021_acs_jafc_0c07816 crossref_primary_10_61186_jhehp_9_2_100 crossref_primary_10_3389_fmicb_2019_01508 crossref_primary_10_1093_femsre_fuad023 crossref_primary_10_5812_archcid_148571 crossref_primary_10_1021_acsinfecdis_0c00389 crossref_primary_10_3168_jds_2020_19350 crossref_primary_10_1016_j_molstruc_2024_139614 crossref_primary_10_3389_fbioe_2021_692466 crossref_primary_10_1007_s00213_019_05224_0 crossref_primary_10_1016_j_jiph_2024_102501 crossref_primary_10_3390_microorganisms11020501 crossref_primary_10_1016_j_chembiol_2020_07_005 crossref_primary_10_3390_ijms25052655 crossref_primary_10_1021_acssynbio_1c00161 crossref_primary_10_1021_acs_jafc_2c00232 crossref_primary_10_3389_fmicb_2025_1526250 crossref_primary_10_1007_s00203_020_02005_8 crossref_primary_10_3390_molecules27092675 crossref_primary_10_1007_s00253_019_10187_5 crossref_primary_10_3390_ani13101633 crossref_primary_10_3390_antibiotics9060330 crossref_primary_10_1016_j_lwt_2019_108915 crossref_primary_10_3390_microorganisms12061230 crossref_primary_10_1038_s42003_020_01511_1 crossref_primary_10_1016_j_ijbiomac_2025_140127 crossref_primary_10_3390_foods9091203 crossref_primary_10_1016_j_bcab_2022_102317 crossref_primary_10_1128_MMBR_00007_19 crossref_primary_10_3389_fmars_2021_659519 crossref_primary_10_1016_j_ijantimicag_2019_03_009 crossref_primary_10_1111_wrr_12909 crossref_primary_10_1038_s41598_023_49466_7 crossref_primary_10_1016_j_micpath_2020_104320 crossref_primary_10_1016_j_copbio_2020_12_022 crossref_primary_10_1186_s12917_024_03985_1 crossref_primary_10_3168_jds_2019_17498 crossref_primary_10_1186_s12864_021_08005_2 crossref_primary_10_1016_j_foodcont_2021_108778 crossref_primary_10_1080_10826068_2023_2209892 crossref_primary_10_1002_adma_202304991 crossref_primary_10_3389_fmicb_2018_03006 crossref_primary_10_3390_microorganisms12071259 crossref_primary_10_1016_j_bmc_2019_06_031 crossref_primary_10_1042_BST20200425 crossref_primary_10_1016_j_lwt_2021_112777 crossref_primary_10_3389_fmicb_2024_1406672 crossref_primary_10_1021_acssynbio_4c00650 crossref_primary_10_3389_fmicb_2020_592220 crossref_primary_10_1111_mmi_14183 crossref_primary_10_1128_AAC_02050_19 crossref_primary_10_3390_foods12193520 crossref_primary_10_1039_D3FO05619H crossref_primary_10_1007_s10570_024_06039_9 crossref_primary_10_3390_antibiotics13050415 crossref_primary_10_3390_microorganisms11020427 crossref_primary_10_1128_AEM_00391_21 crossref_primary_10_1016_j_ijbiomac_2024_135389 crossref_primary_10_1016_j_afres_2025_100693 crossref_primary_10_1159_000543664 crossref_primary_10_1016_j_procbio_2022_09_030 crossref_primary_10_3390_ijms23094685 crossref_primary_10_1186_s12866_024_03400_7 crossref_primary_10_1016_j_ijbiomac_2025_141961 crossref_primary_10_1186_s12934_023_02041_1 crossref_primary_10_1111_aji_13096 crossref_primary_10_1021_jacs_1c09370 crossref_primary_10_1093_femsre_fuaa021 crossref_primary_10_1128_AEM_00186_21 crossref_primary_10_1021_acssynbio_1c00080 crossref_primary_10_3389_fmicb_2020_598789 crossref_primary_10_1007_s12033_022_00584_z crossref_primary_10_1002_ps_5859 crossref_primary_10_1016_j_bios_2022_114809 crossref_primary_10_1128_JB_00639_19 crossref_primary_10_1134_S0006297920110048 crossref_primary_10_1016_j_colsurfb_2021_111965 crossref_primary_10_1139_cjm_2019_0292 crossref_primary_10_1128_mBio_02825_20 crossref_primary_10_5851_kosfa_2022_e48 crossref_primary_10_3390_antibiotics9030128 crossref_primary_10_1021_acsinfecdis_0c00001 crossref_primary_10_3390_ijms22073480 crossref_primary_10_1007_s00018_021_03759_0 crossref_primary_10_3390_ph16081058 crossref_primary_10_3390_pharmaceutics14010076 crossref_primary_10_1016_j_resmic_2021_103836 crossref_primary_10_1038_s41579_024_01045_x crossref_primary_10_3389_fmicb_2020_561060 crossref_primary_10_1016_j_foodres_2022_112363 crossref_primary_10_3390_pharmaceutics13010086 |
Cites_doi | 10.1128/CMR.14.4.933-951.2001 10.1016/j.bbrc.2004.08.144 10.1016/j.peptides.2004.03.016 10.1128/AAC.00883-09 10.1126/science.1121422 10.1021/sb3001084 10.1007/s10989-011-9284-6 10.1128/aem.62.10.3662-3667.1996 10.1074/jbc.M109.026690 10.1128/JB.154.1.1-9.1983 10.1126/science.1129818 10.1128/AEM.02350-06 10.1517/17425255.2011.573478 10.3390/jdb4010007 10.1016/j.peptides.2008.07.016 10.3389/fmicb.2015.00011 10.1016/S0021-9258(18)42830-X 10.1016/j.febslet.2008.06.015 10.1128/AEM.01104-07 10.1016/j.ijantimicag.2011.07.012 10.1016/j.dci.2010.12.011 10.1016/j.cbpb.2009.10.003 10.3389/fmicb.2018.00160 10.1007/s00018-007-7171-2 10.1038/nprot.2006.4 10.1038/nprot.2007.521 10.1016/S0168-1605(99)00139-7 10.1128/aem.57.12.3613-3615.1991 10.1002/psc.2551 10.1074/jbc.270.45.27299 10.1074/jbc.M006770200 10.1038/nm1145 10.1021/bi700106z 10.1038/nrd2004 10.1021/bi050081h 10.1016/S0168-1605(00)00307-X 10.1016/S0167-7799(97)01029-9 10.1074/jbc.M312789200 |
ContentType | Journal Article |
Copyright | Copyright © 2018 American Society for Microbiology. Copyright American Society for Microbiology Jun 15, 2018 Copyright © 2018 American Society for Microbiology. 2018 American Society for Microbiology |
Copyright_xml | – notice: Copyright © 2018 American Society for Microbiology. – notice: Copyright American Society for Microbiology Jun 15, 2018 – notice: Copyright © 2018 American Society for Microbiology. 2018 American Society for Microbiology |
DBID | AAYXX CITATION NPM 7QL 7QO 7SN 7SS 7ST 7T7 7TM 7U9 8FD C1K FR3 H94 M7N P64 RC3 SOI 7X8 5PM |
DOI | 10.1128/AEM.00052-18 |
DatabaseName | CrossRef PubMed Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Environment Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Genetics Abstracts Environment Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed Virology and AIDS Abstracts Technology Research Database Nucleic Acids Abstracts Ecology Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management Entomology Abstracts Genetics Abstracts Biotechnology Research Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Environment Abstracts MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic Virology and AIDS Abstracts PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Economics Engineering Biology |
DocumentTitleAlternate | Engineering Nisin against Gram-Negative Bacteria |
EISSN | 1098-5336 |
ExternalDocumentID | PMC5981070 29625984 10_1128_AEM_00052_18 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: ; – fundername: ; grantid: 201306770012 |
GroupedDBID | --- -~X 0R~ 23M 2WC 39C 4.4 53G 5GY 5RE 5VS 6J9 85S AAGFI AAYXX AAZTW ABOGM ABPPZ ACBTR ACGFO ACIWK ACNCT ACPRK ADBBV ADUKH AENEX AFRAH AGVNZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BKOMP BTFSW CITATION CS3 D0L DIK E.- E3Z EBS EJD F5P GX1 H13 HYE HZ~ K-O KQ8 L7B O9- P2P PQQKQ RHI RNS RPM RSF RXW TAE TN5 TR2 TWZ UHB W8F WH7 WOQ X6Y ~02 ~KM NPM OK1 RHF UCJ Z5M 7QL 7QO 7SN 7SS 7ST 7T7 7TM 7U9 8FD C1K FR3 H94 M7N P64 RC3 SOI 7X8 5PM TAF |
ID | FETCH-LOGICAL-c342t-b875f3da01f028a0f30177b6e883cc275450d8d89f9af3ae3ea23168893d0ea83 |
ISSN | 0099-2240 1098-5336 |
IngestDate | Thu Aug 21 13:20:43 EDT 2025 Thu Jul 10 20:03:26 EDT 2025 Mon Jun 30 08:46:22 EDT 2025 Wed Feb 19 02:36:24 EST 2025 Tue Jul 01 02:20:12 EDT 2025 Thu Apr 24 23:07:39 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | Gram-negative pathogens lantibiotic outer membrane nisin antimicrobial activity antimicrobial peptide |
Language | English |
License | Copyright © 2018 American Society for Microbiology. All Rights Reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c342t-b875f3da01f028a0f30177b6e883cc275450d8d89f9af3ae3ea23168893d0ea83 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Citation Li Q, Montalban-Lopez M, Kuipers OP. 2018. Increasing the antimicrobial activity of nisin-based lantibiotics against Gram-negative pathogens. Appl Environ Microbiol 84:e00052-18. https://doi.org/10.1128/AEM.00052-18. |
OpenAccessLink | https://aem.asm.org/content/aem/84/12/e00052-18.full.pdf |
PMID | 29625984 |
PQID | 2073499240 |
PQPubID | 42251 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5981070 proquest_miscellaneous_2022982397 proquest_journals_2073499240 pubmed_primary_29625984 crossref_citationtrail_10_1128_AEM_00052_18 crossref_primary_10_1128_AEM_00052_18 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2018-06-15 |
PublicationDateYYYYMMDD | 2018-06-15 |
PublicationDate_xml | – month: 06 year: 2018 text: 2018-06-15 day: 15 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Washington – name: 1752 N St., N.W., Washington, DC |
PublicationTitle | Applied and environmental microbiology |
PublicationTitleAlternate | Appl Environ Microbiol |
PublicationYear | 2018 |
Publisher | American Society for Microbiology |
Publisher_xml | – name: American Society for Microbiology |
References | e_1_3_3_17_2 e_1_3_3_16_2 e_1_3_3_19_2 e_1_3_3_38_2 e_1_3_3_18_2 e_1_3_3_39_2 e_1_3_3_13_2 e_1_3_3_12_2 e_1_3_3_15_2 e_1_3_3_34_2 e_1_3_3_14_2 e_1_3_3_35_2 e_1_3_3_32_2 e_1_3_3_33_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_10_2 e_1_3_3_31_2 e_1_3_3_40_2 Sambrook J (e_1_3_3_36_2) 2001 e_1_3_3_6_2 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 e_1_3_3_28_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_24_2 e_1_3_3_23_2 e_1_3_3_26_2 e_1_3_3_25_2 Holo H (e_1_3_3_37_2) 1995; 47 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_41_2 e_1_3_3_3_2 e_1_3_3_21_2 |
References_xml | – ident: e_1_3_3_31_2 doi: 10.1128/CMR.14.4.933-951.2001 – ident: e_1_3_3_21_2 doi: 10.1016/j.bbrc.2004.08.144 – volume-title: Molecular cloning: a laboratory manual year: 2001 ident: e_1_3_3_36_2 – ident: e_1_3_3_19_2 doi: 10.1016/j.peptides.2004.03.016 – ident: e_1_3_3_40_2 doi: 10.1128/AAC.00883-09 – ident: e_1_3_3_6_2 doi: 10.1126/science.1121422 – ident: e_1_3_3_35_2 doi: 10.1021/sb3001084 – ident: e_1_3_3_25_2 doi: 10.1007/s10989-011-9284-6 – ident: e_1_3_3_8_2 doi: 10.1128/aem.62.10.3662-3667.1996 – volume: 47 start-page: 195 year: 1995 ident: e_1_3_3_37_2 article-title: Transformation of Lactococcus by electroporation publication-title: Methods Mol Biol – ident: e_1_3_3_29_2 doi: 10.1074/jbc.M109.026690 – ident: e_1_3_3_34_2 doi: 10.1128/JB.154.1.1-9.1983 – ident: e_1_3_3_13_2 doi: 10.1126/science.1129818 – ident: e_1_3_3_10_2 doi: 10.1128/AEM.02350-06 – ident: e_1_3_3_11_2 doi: 10.1517/17425255.2011.573478 – ident: e_1_3_3_17_2 doi: 10.3390/jdb4010007 – ident: e_1_3_3_18_2 doi: 10.1016/j.peptides.2008.07.016 – ident: e_1_3_3_32_2 doi: 10.3389/fmicb.2015.00011 – ident: e_1_3_3_20_2 doi: 10.1016/S0021-9258(18)42830-X – ident: e_1_3_3_26_2 doi: 10.1016/j.febslet.2008.06.015 – ident: e_1_3_3_27_2 doi: 10.1128/AEM.01104-07 – ident: e_1_3_3_23_2 doi: 10.1016/j.ijantimicag.2011.07.012 – ident: e_1_3_3_22_2 doi: 10.1016/j.dci.2010.12.011 – ident: e_1_3_3_24_2 doi: 10.1016/j.cbpb.2009.10.003 – ident: e_1_3_3_28_2 doi: 10.3389/fmicb.2018.00160 – ident: e_1_3_3_3_2 doi: 10.1007/s00018-007-7171-2 – ident: e_1_3_3_38_2 doi: 10.1038/nprot.2006.4 – ident: e_1_3_3_41_2 doi: 10.1038/nprot.2007.521 – ident: e_1_3_3_15_2 doi: 10.1016/S0168-1605(99)00139-7 – ident: e_1_3_3_16_2 doi: 10.1128/aem.57.12.3613-3615.1991 – ident: e_1_3_3_39_2 doi: 10.1002/psc.2551 – ident: e_1_3_3_7_2 doi: 10.1074/jbc.270.45.27299 – ident: e_1_3_3_12_2 doi: 10.1074/jbc.M006770200 – ident: e_1_3_3_30_2 doi: 10.1038/nm1145 – ident: e_1_3_3_9_2 doi: 10.1021/bi700106z – ident: e_1_3_3_2_2 doi: 10.1038/nrd2004 – ident: e_1_3_3_4_2 doi: 10.1021/bi050081h – ident: e_1_3_3_14_2 doi: 10.1016/S0168-1605(00)00307-X – ident: e_1_3_3_33_2 doi: 10.1016/S0167-7799(97)01029-9 – ident: e_1_3_3_5_2 doi: 10.1074/jbc.M312789200 |
SSID | ssj0004068 |
Score | 2.5628724 |
Snippet | Lantibiotics are ribosomally synthesized and posttranslationally modified antimicrobial compounds containing lanthionine and methyl-lanthionine residues.... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | e00052-18 |
SubjectTerms | Aerogenes Antibiotics Antiinfectives and antibacterials Antimicrobial activity Antimicrobial agents Bacteria Biosynthesis E coli Efflux Genetics and Molecular Biology Gram-negative bacteria Gram-positive bacteria Klebsiella Lantibiotics Membranes Microorganisms Nisin Pathogens Peptides Pseudomonas aeruginosa Reengineering Tails |
Title | Increasing the Antimicrobial Activity of Nisin-Based Lantibiotics against Gram-Negative Pathogens |
URI | https://www.ncbi.nlm.nih.gov/pubmed/29625984 https://www.proquest.com/docview/2073499240 https://www.proquest.com/docview/2022982397 https://pubmed.ncbi.nlm.nih.gov/PMC5981070 |
Volume | 84 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELZgCDEeEBQYgYGMBE-VS-JkjfNY0GBiP9ikTdpb5Dj2iMSSqk0f4K_nLk5SZxRp8BJViV1HufP5O_vuO0LeKRUqQNkhk7GZsij3NZPaREzmQudJLkxummiLk-nBRfT1cu9yfYLfZJfU2UT92phX8j9ShXsgV8yS_QfJ9n8KN-A3yBeuIGG43krGMLkxprzLeJqVdXFdNMxK-OFVWxgC9wQKaMQ-woqVj4_gWxZZUVl-5itZAEAcf1nIa3airywN-CnAwgpGXbrQtcOruNPupMdh9kmxZnPqA3yaKIEzR_nAekDjTJbsqJrbfetjWa50H-JxuCrmbcW2b0slF-PTibsnEQiMnbJZmZ2dTRKGYMGuMta0InMpgMupa3ttebhOx_hmm84xT2G2fzxpziVZa68H1Nk3lrQ-0LBxcbhIoXfa9E4DcZfc4-BTYLmLwzOHWt6fio6yFF-9y5Lg4oM79hC__OGU3IytdcDK-WPyqPUy6MyqzBNyR5cjct_WHf05Ig-6dPTliDx0GCmfErlWKQoqRQcqRTuVopWhjkpRV6Voq1J0oFK0V6ln5OLz_vmnA9ZW4WAqjHjNMvBoTZhLPzCARaVvYEmI42yqhQiV4jFAcD8XuUhMIk0odaglx2poAIRh5ksRPidbZVXqF4RG2Z7IOPrIQmLxMxFEKoMOOo54rALjkXH3bVPVUtRjpZQf6SY5euR933puqVn-0m63E1PaTt5lymFpA2cf5OyRt_1jMK14XiZLXa2wDeeJ4IDYPbJjpdoPxBPcOBCRR-KBvPsGSNs-fFIW3xv6dugWwEL78pav_4psr6fYLtmqFyv9GoBwnb1pFPg3FuC1RQ |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increasing+the+Antimicrobial+Activity+of+Nisin-Based+Lantibiotics+against+Gram-Negative+Pathogens&rft.jtitle=Applied+and+environmental+microbiology&rft.au=Li%2C+Qian&rft.au=Montalban-Lopez%2C+Manuel&rft.au=Kuipers%2C+Oscar+P.&rft.date=2018-06-15&rft.issn=0099-2240&rft.eissn=1098-5336&rft.volume=84&rft.issue=12&rft_id=info:doi/10.1128%2FAEM.00052-18&rft.externalDBID=n%2Fa&rft.externalDocID=10_1128_AEM_00052_18 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0099-2240&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0099-2240&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0099-2240&client=summon |